Mydecine Innovations Group (DB:0NF0) - Aandelenkoers, Nieuws & Analyse

0NF0 Overzicht aandelen

0NF0 fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

De winst is de afgelopen 5 jaar met 8.7% per jaar gegroeid

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( CA$0 )

Heeft geen betekenisvolle marktkapitalisatie ( €333K )

Heeft minder dan 1 jaar cash runway

Negatief eigen vermogen

+ 2 meer risico's

Mydecine Innovations Group Inc. Concurrenten

Biofrontera

XTRA:B8FK

€15.4m

SynBiotic

DUSE:SBX

€27.9m

MPH Health Care

DB:93M1

€101.9m

Redx Pharma

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Mydecine Innovations Group
Historische aandelenkoersen
Huidige aandelenkoers	US$0.003
52 Week Hoogtepunt	US$0.076
52 Week Laag	US$0.0005
Bèta	2.77
11 maand verandering	0%
3 maanden verandering	-80.00%
1 Jaar Verandering	-96.00%
33 jaar verandering	-99.95%
5 jaar verandering	n/a
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0NF0	DE Pharmaceuticals	DE Markt
7D	0%	1.2%	1.3%
1Y	-96.0%	-19.7%	7.9%

Rendement versus industrie: 0NF0 presteerde slechter dan de German Pharmaceuticals -sector, die het afgelopen jaar een rendement van -19.7 % opleverde.

Rendement versus markt: 0NF0 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 7.9 % opleverde.

Prijsvolatiliteit

Is 0NF0's price volatile compared to industry and market?
0NF0 volatility
0NF0 Average Weekly Movement	120.2%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 0NF0 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van 0NF0 is het afgelopen jaar gedaald van 633% naar 120%, maar is nog steeds hoger dan 75% van de German -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	3	Josh Bartch	www.mydecine.com

Mydecine Innovations Group Inc. is een biotechnologiebedrijf dat zich bezighoudt met het onderzoek naar, de ontwikkeling van en de verkoop van psilocybine-producten voor de behandeling van psychische aandoeningen. Het bedrijf richt zich voornamelijk op de behandeling van nicotineverslaving en posttraumatische stressstoornis. Tot de belangrijkste kandidaat-geneesmiddelen behoren MYCO-005.

Mydecine Innovations Group Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Mydecine Innovations Group zich tot de beurswaarde?
0NF0 fundamentele statistieken
Marktkapitalisatie	€315.14k
Inkomsten(TTM)	-€8.41m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is 0NF0 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0NF0 resultatenrekening (TTM)
Inkomsten	CA$0
Kosten van inkomsten	CA$0
Brutowinst	CA$0
Overige uitgaven	CA$12.46m
Inkomsten	-CA$12.46m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.20
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	-37.4%

Hoe presteerde 0NF0 op de lange termijn?

Bekijk historische prestaties en vergelijking

0NF0 Overzicht aandelen

Beloningen

Risicoanalyse

Mydecine Innovations Group Inc. Concurrenten

XTRA:B8FK

€15.4m

DUSE:SBX

€27.9m

DB:93M1

€101.9m

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Recent updates

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Less than half of directors are independent

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

First quarter 2022 earnings released: CA$1.20 loss per share (vs CA$1.25 loss in 1Q 2021)

High number of new and inexperienced directors

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Full year 2021 earnings released

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Third quarter 2021 earnings released: CA$0.019 loss per share (vs CA$0.11 loss in 3Q 2020)

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Second quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.046 loss in 2Q 2020)

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.006 loss in 1Q 2020)

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Chief Compliance Officer ? recently sold €783k worth of stock

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials